Orphan Drugs Market 2018 Outlook and Pipeline Analysis

DALLAS, March 22, 2014 /PRNewswire/ --

ReportsnReports.com offers "Global Orphan Drug Market Outlook 2018", "Global Orphan Drugs Market 2014-2018" and "Global Orphan Drug Pipeline Analysis" research reports in its store.

The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs. The major drivers for companies to increasingly invest in orphan drugs include government incentives for drug development and strong support from the FDA and EU Commission in special protocols. Inspite of pharma companies facing many obstacles in this field, this segment of orphan drugs is likely to have the potential to provide the key to recovery and stability within the market says the report Global  Orphan  Drug  Market  Outlook  2018 available at http://www.reportsnreports.com/reports/274449-global-orphan-drug-market-outlook-2018.html . This research is available at 20% discount on all user types till March 31, 2014.

The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs.

"Global  Orphan  Drug  Market  Outlook  2018"  research  report  provides  comprehensive  insights  on  following  developments  related  to  global  orphan  drug  market: Global & Regional Orphan Drug Market Overview, Orphan Drug Designation Criteria Across Key Markets, Market Specific Reimbursement Policy & Regulatory Framework, Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country and Competitive Landscape talking about Pfizer, Roche, Sanofi, Rare Disease Therapeutics, Glaxosmithkline, Merck, Novartis Pharmaceuticals, Alexion, Celgene, Biogen Idec, Eli Lilly and Bristol Myers Squibb. Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=274449 .

The report titled Global  Orphan  Drugs  Market  2014-2018 forecasts the industry to grow at 5.67% to 2018. has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the Americas, and the EMEA and APAC regions; it also covers the Global Orphan Drugs market landscape and its growth prospects in the coming years. The report (http://www.reportsnreports.com/reports/274574-global-orphan-drugs-market-2014-2018.html ) also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space are Novartis AG, F. Hoffmann-La Roche Ltd., Celgene Corp., Pfizer Inc., and Sanofi S.A. Other vendors mentioned in the report are Actelion Pharmaceuticals Ltd., Alexion Pharmaceuticals Inc., Amgen Inc., Baxter International Inc., Biogen Idec Inc., Bristol-Myers-Squibb Co., GlaxoSmithKline plc, Eli Lilly & Co., Merck KGaA, Novo Nordisk A/S, Onyx Pharmaceuticals Inc., Shire plc, and Vertex Pharmaceuticals Inc. Order a copy of Global  Orphan  Drugs  Market  2014-2018 research report at http://www.reportsnreports.com/Purchase.aspx?name=274574 .

In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry. With close to 65-70 Million people in the US & Europe having some kind of rare disease complaints, the increasing activities around the development of orphan drugs only imply that the appropriate treatments for unmet needs are increasing, thus increasing the profit margins in the future. As the Asian pharmaceutical markets are still in growth stage, the opportunities for orphan drugs in Asia are also immense and getting increasingly popular. It is expected that by 2020, the Asian orphan drugs market would witness steady growth.

The report Global  Orphan  Drug  Pipeline  Analysis gives comprehensive insight on the various orphan designated drugs being developed for the treatment of rare disease. Research report covers all the orphan designated drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Orphan Drug market based upon development process.

Following  parameters  for  each  orphan  designated  drug  profile  in  development  phase  are  covered  in  "Global  Orphan  Drug  Pipeline  Analysis"  research  report  available  athttp://www.reportsnreports.com/reports/271801-global-orphan-drug-pipeline-analysis.html  :

• Drug Profile Overview
• Alternate Names for Drug
• Active Indication
• Phase of Development
• Mechanism of Action
• Brand Name
• Patent Information
• Orphan Designation by Indication, Country & Organisation
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator
• Administrative Route
• Drug Class
• ATC Codes

Global  Orphan  Drug  Pipeline  by  Clinical  Phase:

• Research: 3
• Preclinical: 71
• Clinical: 4
• Phase-I: 61
• Phase-I/II: 71
• Phase-II: 198
• Phase-II/III: 20
• Phase-III: 103
• Preregistration: 26
• Registration: 17
• Marketed: 244
• Unknown: 1

Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=271801. This report is available at 20% discount till March 31, 2014 on all user types.

Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About  Us:

ReportsnReports.com is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Contact:
Priyank Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@reportsandreports.com

Connect  With  Us  on:

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689
LinkedIn: www.linkedin.com/company/reportsnreports
Twitter: https://twitter.com/marketsreports
Pinterest: www.pinterest.com/comeonseo/reportsnreports/